Clinical trial
Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid…
NCT00069277 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00069277 |
|---|---|
| Title | Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors |
| Official title | A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | E7389 |
| Enrollment | 21 |
| Start date | Aug 1, 2003 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Sep 24, 2003 |
| Last update posted | Apr 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: